Michael Klobuchar - Merck Executive Vice President Chief Strategy Officer
| MRK Stock | USD 99.18 0.68 0.68% |
Insider
Michael Klobuchar is Executive Vice President Chief Strategy Officer of Merck Company since 2021.
| Age | 45 |
| Tenure | 3 years |
| Address | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has Return on Asset of 0.1053 % which means that on every $100 spent on assets, it made $0.1053 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2833 %, implying that it generated $0.2833 on every 100 dollars invested. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.03. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Bronson Crouch | Instil Bio | 51 | |
| Thomas Walker | Bio Path Holdings | N/A | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Louis Ploth | Moleculin Biotech | 70 | |
| Anthony MBA | Capricor Therapeutics | 38 | |
| Catherine Kelleher | Capricor Therapeutics | N/A | |
| Uri MD | Assembly Biosciences | 52 | |
| Jacqueline Northcut | Moleculin Biotech | 62 | |
| MBA MD | Moleculin Biotech | N/A | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| Nicole White | Assembly Biosciences | N/A | |
| Jeffery MD | Bio Path Holdings | N/A | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| FACP MD | Moleculin Biotech | 70 | |
| Eduardo Marbn | Capricor Therapeutics | N/A | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Mark Dudley | Instil Bio | N/A | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Dr IV | Assembly Biosciences | 52 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
Management Performance
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.11 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Lead Independent Director | ||
| Johannes Oosthuizen, Senior Health | ||
| Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer | ||
| Scot Ebbinghaus, VP Development | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Arpa Garay, Lead - Human Health Global Marketing | ||
| Dalton III, Principal Finance | ||
| Christine Seidman, Independent Director | ||
| Kathy Warden, Independent Director | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Caroline Litchfield, Chief Financial Officer, Executive Vice President | ||
| Peter Wendell, Independent Director | ||
| Betty Larson, Executive Officer | ||
| Jannie Oosthuizen, Lead - Human Health U.S. | ||
| Jennifer Mauer, VP Communications | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director | ||
| Gregory Lubiniecki, VP Development | ||
| Michael Klobuchar, Executive Vice President Chief Strategy Officer | ||
| Pamela Craig, Independent Director | ||
| Patricia Russo, Independent Director | ||
| David Williams, Executive Vice President Chief Information Chief Information and Digital Officer | ||
| Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Chirfi Guindo, Senior Health | ||
| Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer | ||
| Joerg Koglin, Vice Development | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Thomas Cech, Independent Director | ||
| Stephen Mayo, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Jennifer JD, Executive Counsel | ||
| Peter Dannenbaum, Vice Relations | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Deepak Khanna, Lead - Human Health International | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Gideon Blumenthal, Vice Affairs | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | ||
| Eric MD, Senior Oncology | ||
| Robert JD, President Chairman | ||
| Risa LavizzoMourey, Independent Director |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 274.43 B | ||||
| Shares Outstanding | 2.53 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 79.46 % | ||||
| Number Of Shares Shorted | 26.23 M | ||||
| Price To Earning | 18.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 3.04 | Earnings Share 4.78 | Revenue Per Share 24.931 | Quarterly Revenue Growth 0.044 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.